Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics-Reference-Cited by-同舟云学术

Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics

Published:2018-05-07 Issue:5 Volume:19 Page:945-954
ISSN:1399-543X
Container-title:Pediatric Diabetes
language:en
Short-container-title:Pediatr Diabetes

Author:

Weir Gordon C¹^ORCID,Ehlers Mario R²,Harris Kristina M³,Kanaparthi Sai³,Long Alice⁴,Phippard Deborah³,Weiner Lia J⁵,Jepson Brett⁵,McNamara James G⁶,Koulmanda Maria⁷,Strom Terry B⁷,

Affiliation:

1. Joslin Diabetes Center; Harvard Medical School; Boston Massachusetts

2. Immune Tolerance Network; Clinical Trials Group; San Francisco California

3. Immune Tolerance Network; Biomarker & Discovery Research; Bethesda Maryland

4. Benaroya Research Institute at Virginia Mason; Translational Research Program; Seattle Western Australia

5. Rho Federal Systems Division; Chapel Hill North Carolina

6. National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology and Transplant; Bethesda Maryland

7. Beth Israel Deaconess Medical Center; Harvard Medical School; Boston Massachusetts

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pedi.12660/fullpdf

Reference34 articles.

1. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group;The Diabetes Control and Complications Trial Research Group;Ann Intern Med,1998

2. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset;Stiller;Science,1984

3. Targeted immune interventions for type 1 diabetes: not as easy as it looks!;Rigby;Curr Opin Endocrinol Diabetes Obes,2014

4. Making progress: preserving beta cells in type 1 diabetes;Gallagher;Ann N Y Acad Sci,2011

5. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes;Herold;Diabetes,2005

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset;Clinica Chimica Acta;2023-03

2. Protein glycosylation in urine as a biomarker of diseases;Translational Research;2023-03

3. Novel insights into the relationship between α-1 anti-trypsin with the pathological development of cardio-metabolic disorders;International Immunopharmacology;2022-10

4. Alpha-1 antitrypsin: A novel biomarker and potential therapeutic approach for metabolic diseases;Clinica Chimica Acta;2022-09

5. Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD?;Medicina;2022-08-01